Under the sponsorship of Zein Pharma Pharmaceutical Industries, a scientific launch symposium was held in Hama Governorate to introduce Vonozein (Vonoprazan 10–20 mg).
The symposium brought together a distinguished gathering of leading physicians, gastroenterologists, and healthcare professionals from across the governorate for an in-depth clinical dialogue on modern approaches to managing acid-related disorders and Gastroesophageal Reflux Disease (GERD).
Key Scientific Highlights
Clinical Lecture by Dr. Bishr Daboul: The scientific session featured a presentation detailing the pharmacological profile and distinct mechanism of action of Vonoprazan (a Potassium-Competitive Acid Blocker – PCAB).
Comparative Clinical Benefits: The discussion highlighted how Vonozein delivers faster onset of action, potent acid inhibition, and sustained intragastric pH control compared to traditional PPI therapies.
Interactive Medical Dialogue: Participating clinicians shared insights on real-world treatment challenges, patient adherence, and optimizing therapeutic outcomes in acid-peptic disorders.
Zein Pharma extends its gratitude to all attending physicians and specialists for their participation and scientific engagement, reaffirming our commitment to advancing healthcare solutions and supporting continuous medical education.
#For_Health_For_Life_For_Everyone
